Trusted Resources

Dec 28, 2022
CRISPR’s Quest to Slay Donegal Amy
In the 5th century, in early medieval Ireland, Conall Gulban, an Irish king, gave his name to an area of land at the northwest tip of the Irish coast. His kingdom…
Read more
Nov 23, 2022
Amyloid Nomenclature 2022: Update, Novel Proteins, and Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
The Nomenclature Committee of the International Society of Amyloidosisexternal link, opens in a new tab met at the XVIII International Symposium on Amyloidosis in…
Read more
Nov 14, 2022
Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent After Adjustment for Key Baseline Variables
Amyloid light chain (AL) amyloidosis - a progressive disorder caused by misfolded light chains produced by plasma cells - is associated with high mortality, poor…
Read more
Jul 22, 2022
Efficacy and Safety of Vutrisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy: A Randomized Clinical Trial
Background: The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients…
Read more
Jul 13, 2022
Stem Cell Transplantation Produces Prolonged Survival With Improved Safety in Patients With AL Amyloidosis
AL amyloidosis is a life-threatening disease related to bone marrow cancer, multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e…
Read more
Jun 01, 2022
Guidelines and New Directions in the Therapy and Monitoring of ATTRv Amyloidosis
The recent approval of three drugs for the treatment of amyloid transthyretin (ATTR) amyloidosis, both hereditary and wild-type, has opened a new era in the care of…
Read more
Subscribe to